Davis George Eric 4
4 · BIOMARIN PHARMACEUTICAL INC · Filed Feb 26, 2026
Research Summary
AI-generated summary of this filing
BioMarin (BMRN) EVP George Davis Sells 26,061 Shares
What Happened
George Davis, EVP and Chief Legal Officer of BioMarin Pharmaceutical (BMRN), reported two types of transactions: he was credited with 15,224 performance-based restricted stock units (RSUs) on Feb 25, 2026 (three awards of 6,177; 6,675; and 2,372 RSUs) and sold 26,061 shares in an open-market transaction on Feb 26, 2026 at $61.36 per share for total proceeds of approximately $1,599,103. The RSUs were reported at $0.00 acquisition price because they are awards, not cash purchases.
Key Details
- Transactions reported: RSU awards (A) totaling 15,224 RSUs on 2026-02-25; open-market sale (S) of 26,061 shares on 2026-02-26 at $61.36/share (≈ $1,599,103).
- RSUs were "earned" per company certification on Feb 25, 2026 but shown as $0.00 because they are awards, not purchases.
- Vesting: the earned RSUs vest on March 15, 2026 subject to continued service (see footnote F3); they are convertible 1:1 into common shares when vested (F1).
- Performance basis: the RSUs were earned under performance metrics covering 2023–2025 (relative total shareholder return, development goals, and core operating margin — footnotes F2–F5).
- Shares owned after the sale: not specified in the provided Form 4 excerpt.
- Filing: Report filed Feb 26, 2026 (covers transactions dated Feb 25–26, 2026); no late-filing indication in the excerpt.
Context
The RSU entries are awards earned under multi-year performance criteria but are not yet vested as of the report date; they become actual shares only upon vesting. The Feb 26 transaction was an open-market sale (a routine disposition of existing shares) and should not be taken as commentary on future company performance. Purchases typically carry more immediate bullish signal than awards or sales; this filing mainly documents a sale plus recognition of earned, unvested performance RSUs.
Insider Transaction Report
- Award
Common Stock
[F1][F2][F3]2026-02-25+6,177→ 89,467 total - Award
Common Stock
[F1][F3][F4]2026-02-25+6,675→ 96,142 total - Award
Common Stock
[F1][F3][F5]2026-02-25+2,372→ 98,514 total - Sale
Common Stock
2026-02-26$61.36/sh−26,061$1,599,103→ 72,453 total
Footnotes (5)
- [F1]Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.
- [F2]Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
- [F3]Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events.
- [F4]Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
- [F5]Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.